Exosomes vs. Growth Factors: What Actually Reaches Living Skin

These are the two most expensive shelves in skincare, and the two most poorly explained. One is a messenger. One is an instruction. Understanding the difference is the fastest way to stop overpaying.

When a serum costs three hundred and fifty dollars, you are entitled to know precisely what you are buying. In the advanced regenerative category — the shelf where exosomes and growth factors sit — that information is unusually hard to come by, partly because the science is genuinely complex and partly because complexity is commercially convenient.

So here is the comparison, without the reverence.

Growth factors: the instruction

Growth factors are proteins. Specifically, they are signalling proteins your own cells secrete to tell neighbouring cells what to do — divide, migrate, produce collagen, build new capillaries. EGF tells epidermal cells to proliferate. TGF-β influences collagen deposition. VEGF concerns blood vessel formation.

In skincare they are typically produced through bioengineering — human sequences expressed in yeast, bacteria or plant cells — because harvesting them from human tissue at scale is neither practical nor, for most people, appealing.

A growth factor is a single, specific instruction. That is its strength and its limitation. It is precise, and it is one voice.

Exosomes: the messenger

An exosome is not a molecule. It is a vesicle — a tiny lipid-membrane bubble, roughly 30 to 150 nanometres across, that cells release to communicate with one another. Inside it is cargo: proteins, lipids, and crucially messenger RNA and microRNA.

The distinction matters enormously. A growth factor is a single instruction shouted at a cell. An exosome is a sealed envelope containing an entire set of instructions, delivered directly into the recipient cell by membrane fusion.

That lipid membrane is doing two jobs. It protects the cargo from degradation on the way, and it allows the exosome to merge with a target cell membrane rather than merely knocking on it. It is a delivery system as much as a payload.

A growth factor is a single instruction shouted at a cell. An exosome is a sealed envelope containing an entire set of instructions, hand-delivered.

The problem neither category can talk its way out of

Both are large. Both are fragile. Both were designed by biology to operate inside tissue, not on top of it.

Skin excludes molecules above roughly 500 daltons with considerable efficiency. Growth factors typically run from 6,000 to 50,000 daltons. Exosomes are larger again by orders of magnitude. On paper, neither should get anywhere.

In practice, three things complicate that tidy objection. Skin is not uniformly impermeable — follicular openings and sweat ducts offer routes past the stratum corneum. Formulators use penetration enhancers, liposomal carriers and pH manipulation specifically to widen those routes. And the upper epidermis is not a dead zone: keratinocyte signalling has genuine downstream consequences for barrier quality, inflammation and light reflectance, even if nothing reaches the dermis at all.

What we will not do is pretend the numbers are better than they are. A topical exosome serum is not an injectable. The results you should expect are real but incremental, and they are largely surface results — clarity, evenness, calm, the quality of light coming off the skin.

Stability: the reason freshly activated formats exist

This is the part of the category almost nobody discusses, and it is the most practically important.

Proteins denature. Lipid membranes degrade. Both categories begin losing potency from the moment they are suspended in an aqueous formula, and neither survives a warm shelf, a bathroom windowsill or an eighteen-month supply chain with its activity intact. A growth factor serum that has sat in a warehouse through a Queensland summer is, functionally, an expensive humectant.

This is precisely why two-phase, freshly activated formats exist — a lyophilised powder held separately from its activating solution, combined by the user at the point of first use. It is not theatre. It is the only honest engineering answer to a genuine stability problem.

If a brand sells you a single-bottle exosome serum with a two-year shelf life and no cold chain, you are entitled to ask what exactly is still alive in it.

Which one, for whom

• Growth factors suit skin with a specific, identifiable deficit — post-procedure repair, thin epidermis, a clear healing objective. Precise instruction for a precise problem.

• Exosomes suit skin where the issue is generalised — tone, quality, redness, the diffuse loss of vitality that does not resolve into a single complaint. Broad instruction for a broad problem.

• Neither is a starting point. If your barrier is compromised, repair it first. Regenerative signalling landing on a damaged barrier is money spent on a foundation that is not there.

• Both reward being applied first, to clean, slightly damp skin, before anything occlusive.

The questions worth asking before you spend

1. What is the source? Plant-derived exosomes and human-cell-derived exosomes are different products with different data behind them. The label should say.

2. What is the format? If it is a single bottle at room temperature, ask how stability is maintained.

3. What is the concentration, expressed as particles or as a percentage — not as a marketing adjective?

4. What does the supporting evidence actually measure? In-vitro fibroblast activity is interesting. It is not the same as a human trial on a face.

We carry one product in this category. Not because there is only one good one, but because there were very few where the answers to those four questions were satisfactory.

The Edit

The one regenerative formula we were willing to stock, and the two ways in.